

LIST OF FIGURES

Sr. No.	Title	Page No.
CHAPTER I	INTRODUCTION	
Figure 1	The skin and its appendages	3
Figure 2	Epidermal melanin unit	4
Figure 3	Melanin synthesis pathway	6
Figure 4	Classification of vitiligo	9
Figure 5	Clinical types of vitiligo	10
Figure 6	The triggering factors in vitiligo	11
Figure 7	Reactive oxygen species generation leading to oxidative stress	13
Figure 8	Different pathways for melanocyte destruction	17
Figure 9	Possible cellular and humoral immune mechanisms in vitiligo	36
Figure 10	Activation of tissue ACE	57
Figure 11	Interaction of CTLA4 and B7 molecules of Dendritic APC's	59
Figure 12	The <i>CTLA4</i> gene and its various splice variants	60
Figure 13	Role of PTPN22 in T-cell receptor signaling	62
Figure 14	Protein interactions involving <i>NALP1</i>	66
Figure 15	Inflammasome assembly.	67
Figure 16	Relative positions of selective SNPs in <i>MYG1</i>	68
Figure 17	IFN γ : Mode of Action	70
CHAPTER II	EVALUATION OF AUTOIMMUNE HYPOTHESIS IN VITILIGO PATIENTS	
Figure 1	Antimelanocyte antibody levels in vitiligo patients and controls	114
CHAPTER III A	GENETIC ASSOCIATION OF PROTEIN TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 22 (<i>PTPN22</i>) GENE POLYMORPHISM WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Figure 1	PCR-RFLP analysis of <i>PTPN22</i> 1858C/T SNP	127
CHAPTER III B	GENETIC ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME (<i>ACE</i>) GENE POLYMORPHISM WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Figure 1	PCR analysis of <i>ACE</i> I/D polymorphism	137

CHAPTER III C	MANNAN BINDING LECTIN-2 (<i>MBL2</i>) GENE STRUCTURAL AND PROMOTER POLYMORPHISMS IN GENERALIZED VITILIGO	
Figure 1	PCR-heteroduplex analysis of <i>MBL2</i> exon 1 (codon 52, codon 54 and codon 57) polymorphisms	149
Figure 2	PCR-heteroduplex analysis of <i>MBL2</i> -221 (X/Y) promoter polymorphism	151
CHAPTER IV	INTERFERON-γ (<i>IFNG</i>) GENE INTRON 1 POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Figure 1	Representative gel picture for genotyping of <i>IFNG</i> +874A/T polymorphism by ARMS-PCR	169
Figure 2	High Resolution Melt (HRM) curve analysis for <i>IFNG</i> CA microsatellite (rs3138557) polymorphism	174
Figure 3	Age of onset of the disease in vitiligo patients	176
Figure 4	Relative gene expression of <i>IFNG</i> in controls and vitiligo patients	178
Figure 5	Serum IFN γ levels in controls and vitiligo patients	181
Figure 6	Serum IFN γ levels with respect to <i>IFNG</i> CA microsatellite polymorphism	182
Figure 7	Relative gene expression of <i>ICAM1</i> in controls and vitiligo patients	184
Figure 8	Melt curve analysis of <i>IFNG</i> , <i>ICAM1</i> and <i>GAPDH</i>	185
CHAPTER V	CYTOTOXIC T-LYMPHOCYTE ASSOCIATED ANTIGEN-4 (<i>CTLA4</i>) GENE POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Figure 1	PCR-RFLP analysis of <i>CTLA4</i> exon 1 +49 A/G and 3' UTR CT60A/G polymorphisms	206
Figure 2	Relative gene expression of <i>f</i> <i>CTLA4</i> and <i>s</i> <i>CTLA4</i> in controls and vitiligo patients	209
Figure 3	Genotype - phenotype correlation of exon 1 +49A/G polymorphism of <i>f</i> <i>CTLA4</i> and <i>s</i> <i>CTLA4</i> in controls and vitiligo patients	210
Figure 4	Genotype - phenotype correlation of 3' UTR CT60A/G polymorphism of <i>f</i> <i>CTLA4</i> and <i>s</i> <i>CTLA4</i> in controls and vitiligo patients	211
Figure 5	Expression of human <i>s</i> <i>CTLA4</i> and <i>f</i> <i>CTLA4</i> mRNA ratio in controls and vitiligo patients	212
Figure 6	Expression of human <i>s</i> <i>CTLA4</i> and <i>f</i> <i>CTLA4</i> mRNA ratio with respect to +49A/G and CT60A/G genotypes in controls and patients	213

Figure 7	Amplification curve for Relative gene expression of <i>flCTLA4</i> and <i>sCTLA4</i>	213
CHAPTER VI	MELANOCYTE PROLIFERATING GENE 1 (<i>MYG1</i>) PROMOTER AND STRUCTURAL POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH VITILIGO SUSCEPTIBILITY	
Figure 1	PCR-RFLP analysis of <i>MYG1</i> -119C/G and 11-12 AA/GC polymorphisms	231
Figure 2	Age of onset of the disease in vitiligo patients	235
Figure 3	Relative gene expression of <i>MYG1</i> in controls and vitiligo patients	238
Figure 4	<i>MYG1</i> fold change and expression in different age groups of vitiligo	239
CHAPTER VII	NACHT LEUCINE-RICH REPEAT PROTEIN 1 (<i>NALP1</i>) GENE PROMOTER AND STRUCTURAL POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Figure 1	PCR-RFLP analysis of <i>NALP1</i> A/G (rs2670660) and C/T (rs6502867) polymorphisms	257
Figure 2	TaqMan end point fluoroscence analysis for <i>NALP1</i> A/T (rs12150220)	260
Figure 3	Age of onset of the disease in vitiligo patients	266
Figure 4	Relative gene expression of <i>NALP1</i> in controls and generalized vitiligo patients	268
CHAPTER VIII	DETERMINATION OF CD4+/CD8+ RATIO AND EVALUATION OF CD4+CD25^{hi}FOXP3+ T-REGULATORY CELLS (Tregs) AND THEIR RELATION TO EFFECTOR T-CELLS (Teffs) IN GENERALIZED VITILIGO PATIENTS AND CONTROLS	
Figure 1	Human CD4+ and CD8+ T-cell subsets identified by FACS analysis (representative FACS plots for CD4+ and CD8+ T-cell)	285
Figure 2	CD4+ and CD8+ T-cell counts and CD4+/CD8+ ratio in vitiligo patients and controls	288
Figure 3	CD4+ and CD8+ T-cell counts and CD4+/CD8+ ratio in patients with active and stable vitiligo	289
Figure 4	CD4+ and CD8+ T-cell counts and CD4+/CD8+ ratio in male and female patients with vitiligo	290
Figure 5	Characterization of human Treg (CD4+CD25 ^{hi} FoxP3+) population by FACS analysis (representative FACS plots for Treg (CD4+CD25 ^{hi} FoxP3+) cells)	292
Figure 6	CD4+CD25 ^{hi} Foxp3+ Treg cells in vitiligo patients and controls	294
Figure 7	T-effector (CD4+CD25 ^{low} FoxP3-) cells in	297

	vitiligo patients and controls	
Figure 8	Ratio of Tregs to Teffector (Tregs/Teffs) cells in vitiligo patients and controls	298

LIST OF TABLES

Sr. No.	Title	Page No.
CHAPTER I	INTRODUCTION	
Table 1	Antigens recognized by autoantibodies of vitiligo patients	20
Table 2	Genes that contribute to vitiligo susceptibility	43
Table 3	HLA associations reported in vitiligo	54
Table 4	Susceptibility loci for vitiligo	56
CHAPTER II	EVALUATION OF AUTOIMMUNE HYPOTHESIS IN VITILIGO PATIENTS	
Table 1	Demographic characteristics of vitiligo patients and unaffected controls	111
CHAPTER III A	GENETIC ASSOCIATION OF PROTEIN TYROSINE PHOSPHATASE NON-RECEPTOR TYPE 22 (<i>PTPN22</i>) GENE POLYMORPHISM WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Table 1	Demographic characteristics of generalized vitiligo patients and controls	124
Table 2	Distribution of genotypes and alleles for the 1858C/T SNP of <i>PTPN22</i> in vitiligo patients and controls	127
CHAPTER III B	GENETIC ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME (<i>ACE</i>) GENE POLYMORPHISM WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Table 1	Demographic characteristics of generalized vitiligo patients and unaffected controls	135
Table 2	Distribution of genotypes and alleles for the <i>ACE</i> I/D polymorphism in vitiligo patients and controls	138
CHAPTER III C	MANNAN BINDING LECTIN-2 (<i>MBL2</i>) GENE STRUCTURAL AND PROMOTER POLYMORPHISMS IN GENERALIZED VITILIGO	
Table 1	Demographic characteristics of generalized	146

	vitiligo patients and unaffected controls	
Table 2	Association studies for mannan-binding lectin gene (<i>MBL2</i>) exon 1	150
Table 3	Distribution of alleles and genotypes for the -221 (X/Y; rs7096206) promoter polymorphism of <i>MBL2</i> gene in generalized vitiligo patients and controls	152
Table 4	Distribution of mannan-binding lectin (<i>MBL2</i>) gene combined (structural & promoter) genotypes among generalized vitiligo patients and controls	153
CHAPTER IV	INTERFERON-γ (<i>IFNG</i>) GENE INTRON 1 POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Table 1	Demographic characteristics of generalized vitiligo patients and unaffected controls	164
Table 2	Primers used for <i>IFNG</i> +874A/T (rs2430561) and CA microsatellite (rs3138557) polymorphisms genotyping and gene expression analyses	167
Table 3	Distribution of genotypes and allele frequencies for <i>IFNG</i> +874 A/T (rs2430561) intron 1 polymorphism in generalized vitiligo patients and controls	170
Table 4.	Distribution of genotypes and allele frequencies for <i>IFNG</i> +874 A/T (rs2430561) intron 1 polymorphism in active and stable vitiligo patients	171
Table 5	Association studies for <i>IFNG</i> +874 A/T (rs2430561) intron 1 polymorphism in male and female patients with vitiligo	172
Table 6	Distribution of genotypes and alleles frequencies for <i>IFNG</i> CA microsatellite (rs3138557) polymorphism in generalized vitiligo patients and controls	173
CHAPTER V	CYTOTOXIC T-LYMPHOCYTE ASSOCIATED ANTIGEN-4 (<i>CTLA4</i>) GENE POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Table 1	Demographic characteristics of generalized vitiligo patients and unaffected controls	200
Table 2	Primers used for <i>CTLA4</i> SNPs genotyping and gene expression analysis	202
Table 3	Association studies for <i>CTLA4</i> gene exon 1 +49A/G and 3' UTR CT60A/G polymorphisms in generalized vitiligo patients	207

Table 4	Distribution of haplotypes frequencies for <i>CTLA4</i> gene polymorphisms (+49A/G and CT60A/G) among generalized vitiligo patients and controls	208
CHAPTER VI	MELANOCYTE PROLIFERATING GENE 1 (<i>MYG1</i>) PROMOTER AND STRUCTURAL POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH VITILIGO SUSCEPTIBILITY	
Table 1	Demographic characteristics of vitiligo patients and unaffected controls	225
Table 2	Primers and restriction enzymes used for <i>MYG1</i> SNPs genotyping and gene expression analyses	227
Table 3	Association studies for <i>MYG1</i> gene -119C/G promoter and 11-12AA/GC structural polymorphisms in vitiligo patients from Gujarat	232
Table 4	Association studies for <i>MYG1</i> gene -119C/G promoter and 11-12AA/GC structural polymorphisms in generalized and localized vitiligo patients from Gujarat	233
Table 5	Association studies for <i>MYG1</i> gene -119C/G promoter and 11-12AA/GC structural polymorphisms in male and female patients with vitiligo.	234
Table 6	Association studies for <i>MYG1</i> gene -119C/G promoter and 11-12AA/GC structural polymorphisms in patients with active and stable vitiligo from Gujarat	236
CHAPTER VII	NACHT LEUCINE-RICH REPEAT PROTEIN 1 (<i>NALP1</i>) GENE PROMOTER AND STRUCTURAL POLYMORPHISMS AND THEIR GENOTYPE-PHENOTYPE CORRELATION WITH GENERALIZED VITILIGO SUSCEPTIBILITY	
Table 1	Demographic characteristics of generalized vitiligo patients and unaffected controls	251
Table 2	Primers and restriction enzymes used for <i>NALP1</i> A/G promoter (rs2670660) and T/C intronic (rs6502867) SNPs genotyping and gene expression analyses	253
Table 3	Association studies for <i>NALP1</i> gene, A/G (rs2670660) promoter, T/C (rs6502867) intron and A/T (rs12150220) polymorphisms in vitiligo patients from Gujarat	261
Table 4	Association studies for <i>NALP1</i> gene, A/G (rs2670660) promoter, T/C (rs6502867) intron and A/T (rs12150220) polymorphisms in patients with active and stable vitiligo from Gujarat	262
Table 5	Association studies for <i>NALP1</i> gene, A/G	263

	(rs2670660) promoter, T/C (rs6502867) intron and A/T (rs12150220) polymorphisms in male and female patients with vitiligo	
Table 6.	Distribution of haplotypes frequencies for <i>NALP1</i> gene, A/G (rs2670660) promoter, T/C (rs6502867) intron and A/T (rs12150220; leu155his) polymorphisms among generalized vitiligo patients and controls	264
CHAPTER VIII	DETERMINATION OF CD4+/CD8+ RATIO AND EVALUATION OF CD4+CD25hiFOXP3+ T-REGULATORY CELLS (Tregs) AND THEIR RELATION TO EFFECTOR T-CELLS (Teffs) IN GENERALIZED VITILIGO PATIENTS AND CONTROLS	
Table	Demographic characteristics of vitiligo patients and unaffected controls	281
Table 2	Counts of CD4+ and CD8+ T cells and CD4+/CD8+ ratio in vitiligo patients and controls	286
Table 3	Counts of CD4+ and CD8+ T cells and CD4+/CD8+ ratio in patients with active and stable vitiligo	286
Table 4	Counts of CD4+ and CD8+ T cells and CD4+/CD8+ ratio with respect to age of onset of vitiligo	287